Chlorpropamide

Structural formula
General
Non-proprietary name	Chlorpropamide
other names	Chlorpropamidum; 4-chloro- N - (propylcarbamoyl) benzenesulfonamide;
Molecular formula	C 10 H 13 N 2 O 3 S
Brief description	white crystalline powder
External identifiers / databases
EC number	202-314-5
ECHA InfoCard	100.002.104
PubChem	2727
DrugBank	DB00672
Wikidata	Q1075324
Drug information
ATC code	A10 BB02
Drug class	Antidiabetic drug
properties
Molar mass	276.74 g mol −1
Physical state	firmly
Melting point	126-129 ° C
solubility	almost insoluble in water; easily soluble in chloroform and acetone ;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
H and P phrases	H: 312-332-351
	P: 280
Toxicological data	2000 mg kg −1 ( LD 50 , rat , oral ) ; 580 mg kg −1 ( LD 50 , rat , ip ) ; 1039 mg · kg -1 ( LD 50 , guinea pigs , oral ) ; 1546 mg kg −1 ( LD 50 , mouse , oral ) ; 800 mg kg −1 ( LD 50 , dog , oral ) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Chlorpropamide is a drug from the sulfonylureas class that is used to treat diabetes mellitus . It is a white, crystalline powder.

history

Chlorpropamide was on the market in Germany from 1958 and is currently no longer used. It has been available in Switzerland since 1978, but only in combination with metformin .

pharmacology

Pharmacodynamics

Chlorpropamide increases the effect of the antidiuretic hormone (ADH).

Pharmacokinetics

The half-life in the body is 25–42 hours; the chlorpropamide metabolites are unlikely to be active. Excretion occurs almost exclusively as a water-soluble sodium salt in the urine .

Individual evidence

↑ ^a ^b ^c Entry on chlorpropamide in ChemicalBook , accessed September 19, 2011.
^ ^A ^b Margitta Albinus: Hager's Handbook of Pharmaceutical Practice: Substances E - O. Springer DE, 1993, ISBN 3-540-52688-9 , p. 908 ( limited preview in Google Book search).
↑ ^a ^b data sheet chlorpropamide from Sigma-Aldrich , accessed on October 16, 2016 ( PDF ). .
↑ ^a ^b ^c ^d ^e MSDS. (PDF; 35 kB) Pfizer.
^ ^A ^b Klaus von Werder: Clinical Neuroendocrinology . 2nd edition. Springer Verlag, 2005, ISBN 978-3-540-21864-7 , p. 101.
↑ Entry on chlorpropamide in Pharmawiki , accessed on January 28, 2017.

[chembook-1] Entry on chlorpropamide in ChemicalBook , accessed September 19, 2011.

[hager-2] A ^b Margitta Albinus: Hager's Handbook of Pharmaceutical Practice: Substances E - O. Springer DE, 1993, ISBN 3-540-52688-9 , p. 908 ( limited preview in Google Book search).

[sigma-3] ta sheet chlorpropamide from Sigma-Aldrich , accessed on October 16, 2016 ( PDF ). .

[pfizer-4] MSDS. (PDF; 35 kB) Pfizer.

[werder-5] A ^b Klaus von Werder: Clinical Neuroendocrinology . 2nd edition. Springer Verlag, 2005, ISBN 978-3-540-21864-7 , p. 101.

[6] Entry on chlorpropamide in Pharmawiki , accessed on January 28, 2017.